Stockopedia | Share Prices, Share News and Company Research

Newton introduces ‘large cap laggards’ theme

Friday, Oct 21 2011 by
1

Newton Higher Income fund‘s ‘large cap laggards’ theme focus is on what Newton considers to be larger cash-generative companies with strong balance sheets and relatively stable end-demand.

Examples include blue-chip companies such as: 

  • GlaxoSmithKline
  • Centrica
  • Tesco
  • Vodafone
  • British American Tobacco
  • Unilever

 Sales and earnings expectations for these companies have tended to be relatively modest, but importantly, they also tend to be relatively stable.

Tineke Frikkee, the manager of the Newton Higher Income fund, focus is on dividend income. She expects a prolonged period of low and volatile growth with significant earnings risks looking into 2012 and beyond. In such an environment, the importance of dividend income is likely to rise significantly.

Frikkee believes that “concerns about sovereign debt levels seem set to persist. The sheer scale of the accumulated debt means that how deleveraging occurs – whether in orderly fashion or not – as well as the effect of offsetting actions by authorities, will be critical for all aspects of the investment outlook.”

“With this in mind, we anticipate a prolonged period of relatively low and more volatile growth in many economies as debt is reduced to more manageable levels.

“In this low growth environment, we believe there is significant earnings risk looking into 2012 and beyond, as growth expectations have generally been set too high.

Past low-return periods lead the way

 “As equity returns are likely to be lower in this environment than during the long economic boom seen during 1980 to 2000, we believe the importance of dividend income is likely to rise significantly.”

“During similar past low-return periods, dividend income has typically contributed around 80-90% to a total return, as an increase in multiple tends to be difficult to achieve (and maintain) when future growth opportunities remain uncertain.

 Special Offer: Invest like Buffett, Slater and Greenblatt. Click here for details »

“UK equity dividends have declined for the past three years, but dividend growth has resumed in 2011 and we expect it to continue in 2012.

“On average, we consider company balance sheets to be relatively strong and there is a reasonable amount of headroom in the dividend cover of most companies, giving us confidence that we will see another year of strong dividend growth. However, this is likely to tail off further out”

Downside protection

“In this higher volatility environment, we believe that reducing downside volatility – offering greater capital protection – will be critical in delivering attractive equity returns,” says Frikkee.

“Equities with a higher-than-average dividend yield tend not go down as much as their lower-yielding peers, given the importance of dividends to total returns. As such, we have a bias towards defensive high yield equities, resulting in a portfolio beta below one.

Most of the ‘large cap laggards’ fall into this category.

“As we go through this deleveraging transition, we believe that investors would do well to reduce their risk by focusing on greater earnings certainty,” She concludes, “Dividend income investing provides an attractive option in such an environment.”

We agree!


Disclaimer:  

Steven Dotsch - Managing editor - http://www.dividend-income-investor.com - Guide to Dividend Investing, at: http://www.dividend-income-investor.com/guide-to-dividend-investing/ - Dividend Value Profiles, at:   http://www.dividend-income-investor.com/british-american-tobacco/


Do you like this Post?
Yes
No
1 thumb up
0 thumbs down
Share this post with friends



GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK’s principal pharmaceutical products include medicines in therapeutic areas: respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, antibacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines and human immunodeficiency virus (HIV). The Company operates in three primary areas of business: Pharmaceuticals, Vaccines and Consumer Healthcare. On January 31, 2012, the Company completed the divestment of brands in the United States and Canada to Prestige Brands Holdings. In August 2012, it acquired Human Genome Sciences. On January 30, 2013, GSK acquired additional 29.3% interest in GlaxoSmithKline Consumer Healthcare Ltd. more »

Share Price (Full)
1712.5p
Change
5.0  0.3%
P/E (fwd)
14.3
Yield (fwd)
4.6
Mkt Cap (£m)
82,954

Centrica plc is an integrated energy company. The Company operates in four segments: Downstream UK, Upstream UK, Storage UK and North America. The Downstream UK includes of British Gas operations. The Upstream UK includes Centrica Energy operations. The Storage UK includes Centrica Storage operations. The North America segment includes the operations of Direct Energy. On November 11, 2011, the Company announced that its subsidiary, Direct Energy, had acquired home protection plan business Home Warranty of America. On 1 June 2011, the Company completed the sale of Oxxio B.V. In January 2012, it acquired natural gas retailer Vectren Source from Vectren Corporation. In April 2012, Centrica plc purchased Teradata Data Warehouse Appliance platform, Teradata Logical Data Model, Teradata Analytical Applications. more »

Share Price (Full)
386.9p
Change
0.4  0.1%
P/E (fwd)
13.5
Yield (fwd)
4.6
Mkt Cap (£m)
20,046

Tesco PLC is an international retailer. The activity of the Company is retailing and associated activities in the United Kingdom, the People’s Republic of China, the Czech Republic, Hungary, the Republic of Ireland, India, Malaysia, Poland, Slovakia, South Korea, Thailand, Turkey and the United States. The Company also provides retail banking and insurance services through its subsidiary, Tesco Bank. The services it offers in store, such as optician, pharmacy, phone shop or customer restaurant. As of February 25, 2012, it had over 180 opticians. Click & Collect is a component of its multi-channel offering. Its store and distribution networks give customers the opportunity to pick products whenever it suits them from over 770 stores, close to where they live or work. As of February 25, 2012, it had 45 stores, which offers grocery Click & Collect. In September 2012, it acquired Mobcast. In March 2013, the Company acquired Restaurant Group Giraffe. more »

Share Price (Full)
380.8p
Change
6.9  1.8%
P/E (fwd)
11.5
Yield (fwd)
4.0
Mkt Cap (£m)
30,681



  Is GlaxoSmithKline fundamentally strong or weak? Find out More »


What's your view on this thread? to Comment Now

 
 
You are feeling neutral

Use the £ sign in front of a ticker to turn £VOD into Vodafone PLC

You can track all @StockoChat comments via Twitter